Cargando…

Pathogenicity of Type I Interferons in Mycobacterium tuberculosis

Tuberculosis (TB) is a leading cause of mortality due to infectious disease and rates have increased during the emergence of COVID-19, but many of the factors determining disease severity and progression remain unclear. Type I Interferons (IFNs) have diverse effector functions that regulate innate a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mundra, Akaash, Yegiazaryan, Aram, Karsian, Haig, Alsaigh, Dijla, Bonavida, Victor, Frame, Mitchell, May, Nicole, Gargaloyan, Areg, Abnousian, Arbi, Venketaraman, Vishwanath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965986/
https://www.ncbi.nlm.nih.gov/pubmed/36835324
http://dx.doi.org/10.3390/ijms24043919
_version_ 1784896903502102528
author Mundra, Akaash
Yegiazaryan, Aram
Karsian, Haig
Alsaigh, Dijla
Bonavida, Victor
Frame, Mitchell
May, Nicole
Gargaloyan, Areg
Abnousian, Arbi
Venketaraman, Vishwanath
author_facet Mundra, Akaash
Yegiazaryan, Aram
Karsian, Haig
Alsaigh, Dijla
Bonavida, Victor
Frame, Mitchell
May, Nicole
Gargaloyan, Areg
Abnousian, Arbi
Venketaraman, Vishwanath
author_sort Mundra, Akaash
collection PubMed
description Tuberculosis (TB) is a leading cause of mortality due to infectious disease and rates have increased during the emergence of COVID-19, but many of the factors determining disease severity and progression remain unclear. Type I Interferons (IFNs) have diverse effector functions that regulate innate and adaptive immunity during infection with microorganisms. There is well-documented literature on type I IFNs providing host defense against viruses; however, in this review, we explore the growing body of work that indicates high levels of type I IFNs can have detrimental effects to a host fighting TB infection. We report findings that increased type I IFNs can affect alveolar macrophage and myeloid function, promote pathological neutrophil extracellular trap responses, inhibit production of protective prostaglandin 2, and promote cytosolic cyclic GMP synthase inflammation pathways, and discuss many other relevant findings.
format Online
Article
Text
id pubmed-9965986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99659862023-02-26 Pathogenicity of Type I Interferons in Mycobacterium tuberculosis Mundra, Akaash Yegiazaryan, Aram Karsian, Haig Alsaigh, Dijla Bonavida, Victor Frame, Mitchell May, Nicole Gargaloyan, Areg Abnousian, Arbi Venketaraman, Vishwanath Int J Mol Sci Review Tuberculosis (TB) is a leading cause of mortality due to infectious disease and rates have increased during the emergence of COVID-19, but many of the factors determining disease severity and progression remain unclear. Type I Interferons (IFNs) have diverse effector functions that regulate innate and adaptive immunity during infection with microorganisms. There is well-documented literature on type I IFNs providing host defense against viruses; however, in this review, we explore the growing body of work that indicates high levels of type I IFNs can have detrimental effects to a host fighting TB infection. We report findings that increased type I IFNs can affect alveolar macrophage and myeloid function, promote pathological neutrophil extracellular trap responses, inhibit production of protective prostaglandin 2, and promote cytosolic cyclic GMP synthase inflammation pathways, and discuss many other relevant findings. MDPI 2023-02-15 /pmc/articles/PMC9965986/ /pubmed/36835324 http://dx.doi.org/10.3390/ijms24043919 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mundra, Akaash
Yegiazaryan, Aram
Karsian, Haig
Alsaigh, Dijla
Bonavida, Victor
Frame, Mitchell
May, Nicole
Gargaloyan, Areg
Abnousian, Arbi
Venketaraman, Vishwanath
Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title_full Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title_fullStr Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title_full_unstemmed Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title_short Pathogenicity of Type I Interferons in Mycobacterium tuberculosis
title_sort pathogenicity of type i interferons in mycobacterium tuberculosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965986/
https://www.ncbi.nlm.nih.gov/pubmed/36835324
http://dx.doi.org/10.3390/ijms24043919
work_keys_str_mv AT mundraakaash pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT yegiazaryanaram pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT karsianhaig pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT alsaighdijla pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT bonavidavictor pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT framemitchell pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT maynicole pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT gargaloyanareg pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT abnousianarbi pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis
AT venketaramanvishwanath pathogenicityoftypeiinterferonsinmycobacteriumtuberculosis